echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Is the PD-1 nearing the end of the negotiations to make a lot of money?

    Is the PD-1 nearing the end of the negotiations to make a lot of money?

    • Last Update: 2020-11-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Text . . The Latte Cat 2019 National Health Care Negotiations were officially implemented on January 1, 2020, with a total of 150 drugs participating in the negotiations, resulting in 97, all of which are included in the list of Class B drugs.
    , 70 of the 119 new drugs, including 52 Western and 18 Chinese medicines, were successfully negotiated, with an average price reduction of 60.7 per cent.
    , the only PD-1 monoantigen to enter health insurance, fell 63.7 percent from 7,838 yuan (10ml:100mg/bottle) to 2,843 yuan.
    generally speaking, access to the health insurance directory is only the first step in market access, and while the cost of the first entry threshold can be saved, the subsequent effort is still not to be underestimated.
    then, is the single PD-1 inhibitor that goes into Medicare payments, TheIndili monoanti, selling better than other uninsured equivalents? Note: The actual drug giveaway situation is officially based on the domestic market of 6 PD-1 inhibitors.
    From the approved adaptive point of view, imported PD-1 Pabli pearl monoantitor and Navuliyu monoantitor have been approved 5 and 3 adaptive disorders respectively, Karelli pearl single resistance approved 4 adaptive disorders, for Lei Lizhu approved 2 adaptive disorders, have been involved in lung cancer , liver cancer and other patients with a larger base of adaptive disease types, and as early as the end of the 18th year listed Xindili monoanti and Terripri monoanti only approved an adaptive disease, Cindy monoanti has a price advantage, and Terripley single resistance approved the only adaptive disease prevalence is low, fewer domestic patients. according to
    Junshi Bio 2020 Semi-Annual Report, Ripley monotherapy is conducting more than 30 clinical trials of single-drug treatment and combined therapy worldwide, involving new adaptations such as nasopharyngeal cancer, urethra skin cancer, lung cancer, stomach cancer, esophageal cancer, liver cancer and breast cancer.
    includes 15 key registered clinical trials and one ongoing Phase I Clinical Trial for Multiple Solid Tumors in the United States.
    2020 Semi-Annual Report of Cinda Bio, Xindili monoanti has been accepted for the treatment of first-line treatment of squamous non-small cell lung cancer applications.
    currently, Syndili Monoanti is conducting more than two dozen clinical studies, including more than 10 registered clinical trials.
    , the domestic marketed PD-1 inhibitors, are in intensive preparation, application for more adaptive disorders.
    , under the premise of safety and effectiveness, ensuring the number of adaptive disorders and related patients is the premise that drug sales can blow out.
    source: the company's annual report from the current market sales situation, whether to cut prices into health insurance strategy has changed, it depends to a large extent on whether there is a strong sales, promotion team behind.
    In terms of market sales, both drugs, which are also mono-adaptive drugs, had higher sales costs in the first half of this year than in the same period last year, but Thepril's share of sales costs increased from 41.30 per cent in 19 years to 59.38 per cent, while Syndicate's fell from 77.43 per cent to 59.76 per cent.
    although the proportion of Syndilly's unitarian sales expenses decreased, the increase in absolute sales costs meant that sales grew faster in the event of higher sales costs." the most important reason why
    can achieve the above positive results is that Xinda Bio did not reduce its sales force by entering Medicare, but instead took full advantage of the PD-1 inhibitor, which is the only one that entered Medicare, to accelerate the coverage of hospital products in first- and second-tier cities.
    announcement, the sales and marketing team of Xindili mono-anti-injection increased from 700 on December 31, 2019 to 1,100 on June 30, 2020, an increase of 40 0; coverage expanded from 2,000 hospitals and 500 DTP pharmacies in December 19 to 3,500 hospitals and 900 DTP pharmacies in 300 cities in June 2010.
    , six PD-1 inhibitors have been listed in the public hospitals in the Ameda sample, and there are 5 kinds of sales data for 2019-2020.
    , there are no official statistics, according to the Ameda sample public hospital database and annual business report estimates, the variety is expected to be the first half of 2020 national sales of about 1 billion yuan.
    and Karelli Zhu both have third-line Hodgkin's lymphoma treatment.
    the background of the expansion of the new drug market, take advantage of the rapid release of medical insurance.
    58.35 per cent of Its sales contributed only 22.03 per cent of the market share as a result of lower payment prices.
    And With the advantages of ADHD and strong sales promotion capabilities, in the year or so since its approval, In the Ameda sample public hospital database, Karelli Pearl sales accounted for only 11.41 percent, but sales jumped to 30 percent of the PD-1 market.
    such a huge spread strength, it seems that Hengrui hit a high price base.
    , it seems, there is little temptation to get into health insurance compared to Mr. Hindley.
    , the authenticity of some drug marketing has been questioned by some.
    Photo Source: A "brochure" of a PD-1 inhibitor for users of a forum on a social forum, although it does not specify unsealed indications, appears to contain some hint from a series of clinical data published therein.
    there is no problem inducing doctors or patients to use drugs for amplification? Has been questioned by some netizens.
    the likes of this kind of side-scrubbing behavior, whether it can be recognized, is still to be investigated.
    PD-1 as an example, innovative drugs should be based on market capacity and demand.
    enterprises need to weigh the proportion between patient population and promotion costs, and comprehensively determine the market cost and total sales of innovative drugs in the two cases of entry and non-entry into health insurance.
    the decisions that companies make are more rational.
    with the 2020 health care negotiations approaching.
    Xiong Xianjun, the head of the National People's Bank of China, said in an interview, "... But on the other hand, China is still a developing country, basic health insurance financing is limited, in 2019 the per capita financing of residents' health insurance is only about 800 yuan, of which two-thirds still comes from financial subsidies ... In this year's health insurance drug catalog access negotiations, we will organize experts to strictly grasp the relevant standards and conditions, but also ask the community and pharmaceutical enterprises to have reasonable expectations of the negotiations, may not be very high success rate.
    " then, in this year's success rate will not be very high premise, innovative drugs want to enter health insurance, we must plan the scope of price reduction and promotion team focus, according to the product ADHD area layout, planning to go through health insurance sales first.
    a clear understanding of the competitive environment if we want to get health insurance or not.
    market by cutting prices when sales resources are insufficient, or by not having to cut prices with strong sales capabilities, or by sending sales teams and health care into the market... Now, going into health insurance doesn't mean everything is good, and not being covered doesn't mean losing competitiveness at all.
    with the start of this year's health care negotiations, each family has submitted the health care negotiation declaration information, in the end how much, how much patients will pay, purchasing power can support not reduce prices? On the one hand, it is necessary to make profit margins for innovative drugs, on the other hand, we should also plan how many resources can be invested in the market, to see if the sales team has the ability to promote similar products.
    price-cutting drugs can be expanded through the expansion of adaptive disorders, channels to expand the use of more patients;
    References. Jean L Bolognia. Dermatology (Textbook Edition) .M. Zhu Xuejun, Wang Baoxuan, Sun Jianfang, etc. Version 2. Beijing: Peking University Medical Press, 2015.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.